These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22563014)

  • 1. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
    Baz M; Abed Y; Boivin G
    Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
    Pizzorno A; Bouhy X; Abed Y; Boivin G
    J Infect Dis; 2011 Jan; 203(1):25-31. PubMed ID: 21148493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
    McKimm-Breschkin JL; Williams J; Barrett S; Jachno K; McDonald M; Mohr PG; Saito T; Tashiro M
    J Antimicrob Chemother; 2013 Oct; 68(10):2210-21. PubMed ID: 23759505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
    Duwe SC; Wedde M; Birkner P; Schweiger B
    Antiviral Res; 2011 Jan; 89(1):115-8. PubMed ID: 21070812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
    Zaraket H; Dapat C; Ghanem S; Ali Z; Lteif M; Kondo H; Dapat IC; Saito K; Kayali G; Suzuki H; Dbaibo G; Saito R
    Intervirology; 2014; 57(6):344-52. PubMed ID: 25301400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
    Hurt AC; Holien JK; Parker M; Kelso A; Barr IG
    J Virol; 2009 Oct; 83(20):10366-73. PubMed ID: 19641000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.